2010
DOI: 10.1001/archgenpsychiatry.2010.107
|View full text |Cite
|
Sign up to set email alerts
|

Modification of Cognitive Performance in Schizophrenia by Complexin 2 Gene Polymorphisms

Abstract: The PGAS allows identification of marker-associated clinical/biological traits. Current cognitive performance in schizophrenic patients is modified by CPLX2 variants modulating posttranscriptional gene expression.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
114
0
1

Year Published

2011
2011
2015
2015

Publication Types

Select...
8

Relationship

7
1

Authors

Journals

citations
Cited by 89 publications
(117 citation statements)
references
References 73 publications
0
114
0
1
Order By: Relevance
“…Regarding the discovery sample (total of N = 2,495), subject selection was unbiased, that is, sera collection was concluded before specific serological analysis was planned: Schizophrenic patients (N = 1,076) were recruited between 2005 and 2011 at 23 German sites for the Göttin-gen Research Association for Schizophrenia (GRAS) data collection. Patients fulfilling Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (11) criteria for schizophrenia (81.4%) or schizoaffective disorder (18.6%) were included regardless of disease stage (8,12). Healthy GRAS controls were anonymized blood donors (N = 1,271; Transfusion Medicine, Göttingen, Department of Transfusion Medicine, University Medicine of Göttingen).…”
Section: Participantsmentioning
confidence: 99%
See 1 more Smart Citation
“…Regarding the discovery sample (total of N = 2,495), subject selection was unbiased, that is, sera collection was concluded before specific serological analysis was planned: Schizophrenic patients (N = 1,076) were recruited between 2005 and 2011 at 23 German sites for the Göttin-gen Research Association for Schizophrenia (GRAS) data collection. Patients fulfilling Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (11) criteria for schizophrenia (81.4%) or schizoaffective disorder (18.6%) were included regardless of disease stage (8,12). Healthy GRAS controls were anonymized blood donors (N = 1,271; Transfusion Medicine, Göttingen, Department of Transfusion Medicine, University Medicine of Göttingen).…”
Section: Participantsmentioning
confidence: 99%
“…Of all schizophrenic (GRAS) patients, extensive phenotypical characterization was conducted as referenced previously (8,12). Age of onset, age at first psychotic episode, positive and negative syndrome scale (PANSS) scores, chlorpromazine equivalents (CPZ), neurological symptoms (Cambridge Neurological Inventory [CNI]) including fine motor skills (MacQuarrie dotting/tapping), current cognitive functioning (composite score comprising reasoning, executive function, verbal learning and memory), global assessment of functioning (GAF), Parkinsonism, hard neurological signs, motor coordination, sensory integration and gait were employed as disease characteristics.…”
Section: Phenotypical Analysesmentioning
confidence: 99%
“…Complexins are conserved in invertebrates, which usually also express soluble and membrane-anchored forms (5,6). In human patients, significant evidence links complexin expression to schizophrenia, although it is unclear whether the observed changes are cause or consequence of the disorder (7)(8)(9)(10).…”
mentioning
confidence: 99%
“…The schizophrenic patient sample (n = 1,086) was recruited across 23 sites throughout Germany in the cross-sectional GRAS study and most comprehensively phenotyped (31,32). The study was approved by the Ethics Committee of the GeorgAugust-University (Göttingen, Germany) and the review boards of participating centers and complies with the Declaration of Helsinki.…”
Section: Human Samplementioning
confidence: 99%
“…To explore the function of Baiap3, we combined the behavioral analysis of Baiap3 knockout (KO) mice with a phenotype-based genetic association study (PGAS) of the human BAIAP3 gene by using the Göttingen Research Association for Schizophrenia (GRAS) database (31,32). Using this two-pronged approach, we identify Baiap3/BAIAP3 as the first genetic risk marker for anxiety and benzodiazepine abuse in both mice and humans.…”
Section: Introductionmentioning
confidence: 99%